24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904

Medical Disorders
Basic InformationLookupsLatest News
AHA News: Emphysema May Raise Risk of Ruptured AneurysmsNew Facial Bone Might Someday Be Grown From the Patient's RibWhat Works Best for Women Struggling With a Leaky Bladder?Your Apple Watch Might Help Spot a Dangerous Irregular HeartbeatDocs Back Away From Low-Dose Aspirin for Heart Attack PreventionAHA News: Overweight Kids at Higher Risk for Blood Clots as AdultsEbola Survivors Continue to Suffer Years After RecoveryFewer Boys Are Suffering Head Injuries, But Rate Rises for GirlsAHA News: Black Woman in Their 50s Face Especially High Stroke RiskNew Drug Could Help Those With Tough-to-Treat CholesterolWhen Can Kids Return to Play After a Concussion?Need to Be Vaccinated? Try Your Local PharmacyOne-Third of U.S. Kids Have Back Pain, Study SaysBlacks, Hispanics Bear Burden of Air Pollution: StudyChickens Help Scientists Pinpoint Origin of Rare, Deadly VirusDry Eye and Migraines Might Be Linked: StudySkin Fungi May Be Tied to Bowel DiseaseYo-Yo Dieting Can Take a Toll on Your HeartAHA News: Opioid Meds Pose Danger to Kidney Disease PatientsHealth Tip: UTI Warning SignsStaph Infections Drop, but Levels Still Worry U.S. Health OfficialsTreatment May Allow Allergic Kids to Eat Eggs Safely: StudyAcne Drug Accutane May Not Depress Mood After AllHealth Tip: Preventing Carpal TunnelMajor Flooding Can Bring Skin Infection DangersSmall Trial Provides New Hope Against Parkinson's DiseaseIs Your Hand Pain Arthritis, Carpal Tunnel or Something Else?California Parents Are Getting Around Vaccine Law, Fueling Measles OutbreaksSeniors With UTIs Need Antibiotics ASAP, Study SaysWhy Do Some Kids With Eczema Develop Food Allergies?High-Fiber Diet May Help Gut 'Microbiome' Battle MelanomaTick Bites More Likely to Cause Red Meat Allergy Than ThoughtWalking, Not Riding, Boosts Health in Golfers With Knee WoesIs At-Home Stool Test a Viable Alternative to Colonoscopy?After Peanut Allergy Rx, Eating Small Bits of Peanut Might Help: StudyA Hard Look at Smoking's Effect on VisionPeanut Allergy Patch Shows Middling Results in TrialToxins in Home Furnishings Can Be Passed on to KidsKratom-Related Poisonings Are Soaring, Study FindsFDA Aims to Strengthen Sunscreen RulesBrain Condition CTE Seen in H.S. Football Players: StudyPregnant Women Should Delay Gallbladder Surgery, Study FindsGut Microbes May Help Drive Lupus, Study FindsMost Hip, Knee Replacements Last Decades, Study FindsAHA News: Living Near Convenience Stores Could Raise Risk of Artery-Clogging ConditionPossible Parkinson's 'Pandemic' Looms: Report'Apple-Shaped' Body? 'Pear-Shaped'? Your Genes May TellProtect Your Aging Eyes From Macular DegenerationKidney Failure Patients Face Higher Risk of Cancer DeathHow Inactivity and Junk Food Can Harm Your Brain
Questions and AnswersLinks
Related Topics


New Hepatitis Meds Are Saving Lives: Study

HealthDay News
by -- Robert Preidt
Updated: Feb 12th 2019

new article illustration

TUESDAY, Feb. 12, 2019 (HealthDay News) -- New (and pricey) hepatitis C medicines, such as Harvoni and Sovaldi, are living up to their promise and greatly reducing patients' odds for liver cancer and death, a new French study finds.

The news came as little surprise to one U.S. liver expert.

The advent of this class of drugs "has led to almost universal cure of chronic hepatitis C infection," said Dr. David Bernstein, chief of hepatology at Northwell Health in Manhasset, N.Y.

Bernstein believes "this large study provides the best evidence to date to support the recommendations that all patients with chronic hepatitis C infection be treated with [these drugs]."

According to background data in the study, about 71 million people worldwide have chronic hepatitis C infection, which can cause debilitating or fatal illnesses such as cirrhosis, liver disease and liver cancer. Over the last 15 years, these complications have tripled and it's predicted that they'll peak between 2030 and 2035, the researchers said.

The new research was funded by drugmakers and included nearly 9,900 patients in France.

About three-quarters of the patients were treated with the newer class of drugs, called "direct-acting antivirals," while the other one-quarter were not.

Direct-acting antivirals work quickly -- over a course of about three months -- to push liver-damaging hepatitis C virus to undetectable levels in patients' blood.

In the study, over a median follow-up of nearly three years, 218 patients died and 258 were diagnosed with liver cancer.

Compared to untreated patients, those treated with direct-acting antivirals were 52 percent less likely to die prematurely (84 deaths per 10,000 in untreated patients versus 40 per 10,000 in treated patients). In addition, patients who were treated were 33 percent less likely to be diagnosed with liver cancer within a year (129 cases per 10,000 in untreated patients versus 86 per 10,000 in treated patients), the researchers reported.

In a subgroup of more than 3,000 patients with cirrhosis of the liver at the start of the study, the same reductions in risk were seen in patients who received the new medicines, providing they achieved an undetectable level of hepatitis C virus in their blood.

The study, published Feb. 11 in The Lancet, received funding from the drug companies MSD, Janssen, Gilead (maker of direct-acting antivirals Harvoni, Sovaldi, Vosevi and Epclusa), AbbVie (maker of Mavyret), Bristol-Myers Squibb (maker of Daklinza), and Roche.

According to the researchers, this is the first study to show the effectiveness of direct-acting antivirals in patients with chronic hepatitis C infection. The study authors said that they believe the findings make a strong argument for expanded use of the drugs.

"We saw a reduction of risk for complications related to the disease, and to mortality, and believe this treatment should be considered for all patients with chronic hepatitis C infection," lead researcher Fabrice Carrat of Sorbonne University, Paris, said in a journal news release.

In an accompanying journal commentary, Dr. Raymond Chung, director of the Liver Center at Massachusetts General Hospital in Boston, pointed out that the findings "provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic hepatitis C viral infection."

One remaining issue has been the cost of direct-acting antivirals, which were originally priced at about $90,000 for the required three-month course. Bernstein said those concerns have eased somewhat, but not completely.

"While prices of hepatitis C therapies have decreased significantly in the U.S. over the past four years, making them affordable to most patients, access to these life-changing and -saving medications remains difficult amongst certain patient groups," he said.

"Certain states have imposed restrictions on their availability based upon extent of liver damage, presence of sobriety, and restrictions on which providers can prescribe these therapies," Bernstein noted.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more on hepatitis C.